

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	2
-------	---	----	---

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	10/809,226
Filing Date	March 25, 2004
First Named Inventor	Julie Dyll
Art Unit	1648
Examiner Name	M. Franco Salvoza
Attorney Docket Number	3219/7

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/809,226
				Filing Date	March 25, 2004
				First Named Inventor	Julie Dyall
				Art Unit	1648
				Examiner Name	M. Franco Salvoza
Sheet	2	of	2	Attorney Docket Number	3219/7

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	1	ELNIFRO E.M. et al., "Multiplex PCR: Optimization and Application in Diagnostic Virology"; Clinical Microbiology Reviews, 2000, Vol. 13, No. 4, pp 559-70.		
	2	FRENKEL N. et al., "Miniview: The Herpes simplex virus amplicon – a versatile defective virus vector"; Gene Therapy, 1994, Vol. 1, suppl. 1, pp S40-S46.		
	3	FRESE M. et al., "Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway"; Journal of General Virology, 2001, Vol. 82, pp 723-33.		
	4	MACDONALD G.H. and JOHNSTON R.E., "Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis"; Journal of Virology, 2000, Vol. 74, No. 2, pp 914-22.		
	5	MAKENZIE J. M. et al., "Stable Expression of Noncytopathic Kunjin Replicons Simulates Both Ultrastructural and Biochemical Characteristics Observed during Replication of Kunjin Virus"; Virology, 2001, Vol. 279, No. 1, pp 161-72.		
	6	OLIVO P.D. et al., "Detection and Quantitation of Human Respiratory Syncytial Virus (RSV) Using Minigenome cDNA and a Sindbis Virus Replicon: A Prototype Assay for Negative-Strand RNA Viruses"; Virology, 1998, Vol. 251, No. 1, pp 198-205.		
	7	PIETSCHMANN T. et al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs"; Journal of Virology, 2001, Vol. 75, No. 3, pp 1252-64.		
	8	VAN DINTEN L.C. et al., "The Predicted Metal-Binding Region of the Arterivirus Helicase Protein Is Involved in Subgenomic mRNA Synthesis, Genome Replication, and Virion Biogenesis"; Journal of Virology, 2000, Vol. 74, No. 11, pp 5213-23.		
	9	VET J.A.M. et al., "Multiplex detection of four pathogenic retroviruses using molecular beacons"; Proc. Natl. Acad. Sci. USA, 1999, Vol. 96, pp 6394-99.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.